[
  {
    "ts": null,
    "headline": "“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List",
    "summary": "TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National He",
    "url": "https://finnhub.io/api/news?id=d39ffa07d805ee9a4fa3cd751544b7ac0680219c163aca69f375b5fe84095493",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765236600,
      "headline": "“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List",
      "id": 137738176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National He",
      "url": "https://finnhub.io/api/news?id=d39ffa07d805ee9a4fa3cd751544b7ac0680219c163aca69f375b5fe84095493"
    }
  },
  {
    "ts": null,
    "headline": "Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.",
    "summary": "Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.",
    "url": "https://finnhub.io/api/news?id=01244a0d14798360e96b1cb747b5cdab4cd19b32a8f893ef84fbb33c2ccf8fab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765191600,
      "headline": "Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.",
      "id": 137732369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.",
      "url": "https://finnhub.io/api/news?id=01244a0d14798360e96b1cb747b5cdab4cd19b32a8f893ef84fbb33c2ccf8fab"
    }
  },
  {
    "ts": null,
    "headline": "Is Biogen Stock Outperforming the Dow?",
    "summary": "Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=d53bc1022d854a2bf282e3b734506443ac4cfbcb0fdb00c3610f7936b76f0656",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765183064,
      "headline": "Is Biogen Stock Outperforming the Dow?",
      "id": 137732824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=d53bc1022d854a2bf282e3b734506443ac4cfbcb0fdb00c3610f7936b76f0656"
    }
  },
  {
    "ts": null,
    "headline": "1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds",
    "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
    "url": "https://finnhub.io/api/news?id=9750ebc7566472dfb3afaf2d8a273b5c0ebde127db1323dae3e267ec7f138a82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765168368,
      "headline": "1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds",
      "id": 137732616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
      "url": "https://finnhub.io/api/news?id=9750ebc7566472dfb3afaf2d8a273b5c0ebde127db1323dae3e267ec7f138a82"
    }
  }
]